Abstract:Since PTP1B enzyme was discovered in 1988, it has captured the research community's attention. This landmark discovery has stimulated numerous research studies on a variety of human diseases, including cancer, inflammation, and diabetes. Tremendous progress has been made in finding PTP1B inhibitors and exploring PTP1B regulatory mechanisms. This review investigates for the natural PTP1B inhibitors, and focuses on the common characteristics of the discovered structures and structure-activity relationships. To f… Show more
“…PTP1B is a negative regulator of insulin signaling via dephosphorylation of the insulin receptor tyrosine residues and downstream substrates to reduce the role of insulin [ 62 ]. It is well accepted that this enzyme is a promising target for hypoglycemic agent discovery, and a recent review deals with PTP1B inhibitors from natural sources [ 63 ]. In the past decade, several BPs with hypoglycemic activity targeting PTB1B have been discovered.…”
Section: Bioactivities Of Bps and Potential Use In Medicinementioning
Marine algae contain various bromophenols that have been shown to possess a variety of biological activities, including antiradical, antimicrobial, anticancer, antidiabetic, anti-inflammatory effects, and so on. Here, we briefly review the recent progress of these marine algae biomaterials and their derivatives from 2011 to 2020, with respect to structure, bioactivities, and their potential application as pharmaceuticals.
“…PTP1B is a negative regulator of insulin signaling via dephosphorylation of the insulin receptor tyrosine residues and downstream substrates to reduce the role of insulin [ 62 ]. It is well accepted that this enzyme is a promising target for hypoglycemic agent discovery, and a recent review deals with PTP1B inhibitors from natural sources [ 63 ]. In the past decade, several BPs with hypoglycemic activity targeting PTB1B have been discovered.…”
Section: Bioactivities Of Bps and Potential Use In Medicinementioning
Marine algae contain various bromophenols that have been shown to possess a variety of biological activities, including antiradical, antimicrobial, anticancer, antidiabetic, anti-inflammatory effects, and so on. Here, we briefly review the recent progress of these marine algae biomaterials and their derivatives from 2011 to 2020, with respect to structure, bioactivities, and their potential application as pharmaceuticals.
“…In addition, a methine proton at δ H 5.88 (1H, m, H-11) exhibited long-range correlations with carbon signals at δ C 77.6 (C-8), 49.8 (C-10), 48.4 (C-13), and 166.3 (C-7 ), indicating the second benzoyl group located at C-11. All the above data revealed that compound 1 was a pimarane-type diterpene [9,[29][30][31] and was identical with siphonol A, except only for a lack of an acetyl moiety at C-7. The downfield chemical shift of methine proton H-7 (δ H 5.51 ppm) in siphonol A [13] is quite different from the upfield chemical shift of methine proton H-7 (δ H 4.32 ppm) in 1.…”
Section: Structure Elucidationmentioning
confidence: 90%
“…There are many PTP1B inhibitors from medicinal plants. Up to now, around 56 families of genera from the natural source were found to inhibit PTP1B activity [9]. Among them, some plants and their secondary metabolites are derived from desert and steppe in the Middle East, such as Artemisia judaica, Centaurium erythraea, Achillea santolina, Capparis spinosa, Moringa peregrina, Retama raetam, Terminalia chebula, and Ziziphus spina-christi [10].…”
Seven pimarane diterpenes (1–7) were isolated from Orthosiphon stamineus Benth. by assay-guided isolation. All of the isolates possessed a 2-deoxy-2-((7-nitro-2,1,3-benzoxadiazol-4-yl)amino)-d-glucose uptake effect in 3T3-L1 adipocytes at concentrations of 5 and 10 μM. Most of them showed potent inhibition against protein tyrosine phosphatase 1B with IC50 values ranging from 0.33 to 9.84 μM. In the kinetic study, all inhibition types were exposed for the examined potencies, including mixed-competitive (1), non-competitives (3 and 5), competitive (6), and uncompetitive (7). The results suggested that O. stamineus and its pimarane diterpenes might exert the hypoglycemic effect via the insulin signaling pathway targeting inhibition of protein tyrosine phosphatase 1B (PTP1B) activity.
“…Hence, it is urgent to identify potent and selective small-molecular PTP1B inhibitors. Natural products, including fatty acids, phenolics, terpenoids, steroids and alkaloids, provide a great amount of PTP1B inhibitors with structural diversity [ 5 , 6 ].…”
Protein-tyrosine phosphatase 1B (PTP1B) has been considered as a promising target for treating insulin resistance. In searching for naturally occurring PTB1B antagonists, two new pimarane diterpenoids, named 2α-hydroxy-7-oxo-pimara-8(9),15-diene (1) and 19-hydroxy-2α-acetoxy-7-oxo-pimara-8(9),15-diene (2), were isolated from the seeds of Caesalpinia minax. Their structures were determined by extensive analysis of NMR and HR-ESIMS data, and their absolute configurations were determined by electronic circular dichroism (ECD) spectra. Compound 1 was disclosed as a competitive inhibitor of PTP1B with an IC50 (the half-maximal inhibitory concentration) value of 19.44 ± 2.39 µM and a Ki (inhibition constant) value of 13.69 ± 2.72 μM. Moreover, compound 1 dose-dependently promoted insulin-stimulated glucose uptake in C2C12 myotubes through activating insulin signaling pathway. Compound 1 might be further developed as an insulin sensitizer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.